Supplementary Material 0813.docx (636.18 kB)

epi-2021-0230 Suppl. Material

dataset

posted on 2021-09-16, 09:39 authored by Yan Li, Bingjing LiBingjing Li, Lixiang Li, Yu Yu, Xiang Gu, Chang Liu, Xinggui Long, Yanbo Yu, Xiuli Zuo

Supplementary Table 1. Overall sample information and patients’ characteristics.

Supplementary Table 2. Primer sequences for qRT-PCR

Supplementary Table 3. Four miRNAs expression level of UC patients and HCs in miRNA sequencing data

Supplementary Figure 1 Correlation analysis of test samples. (A) CircRNAs data correlation analysis of test samples. (B) MiRNAs data correlation analysis of test samples. (C) MRNAs data correlation analysis of test samples.

Supplementary Figure 2 Comparative analysis of hsa_circ_0001021 from UC patients treated with or without medicine. (A) Comparative analysis of hsa_circ_0001021 from UC patients treated with or without 5-ASA. (B) Comparative analysis of hsa_circ_0001021 from UC patients treated with or without steroids. NS, nonsignificant.